Merck Life Science is thrilled to announce the commencement of commercial production at our first Good Manufacturing Practice (GMP) compliant manufacturing line for cell culture media in China. This milestone marks a significant step forward in our commitment to supporting the biopharmaceutical industry in the region.

The €6.6 million investment at our Life Science Center in Nantong is poised to address the rising demand for high-quality custom cell culture media essential for biopharmaceuticals, vaccines, and novel therapeutics. This strategic investment underscores Merck Life Science’s unwavering commitment and confidence in the burgeoning China biopharma market.

“Our new GMP compliant manufacturing line in Nantong is a testament to our dedication to meeting the evolving needs of the biopharmaceutical industry,” said Spokesperson at Merck. “We are proud to support the development of life-saving therapies and to contribute to the growth of China’s biopharma sector.”

The Nantong facility is equipped with state-of-the-art technology and adheres to the highest standards of quality and safety. It will play a crucial role in advancing the production of cell culture media, ensuring a reliable supply for our customers.